Rémi Letestu

2.5k total citations
52 papers, 1.1k citations indexed

About

Rémi Letestu is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Rémi Letestu has authored 52 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 22 papers in Immunology and 21 papers in Pathology and Forensic Medicine. Recurrent topics in Rémi Letestu's work include Chronic Lymphocytic Leukemia Research (31 papers), Lymphoma Diagnosis and Treatment (20 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). Rémi Letestu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (31 papers), Lymphoma Diagnosis and Treatment (20 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). Rémi Letestu collaborates with scholars based in France, Belgium and Australia. Rémi Letestu's co-authors include Florence Ajchenbaum‐Cymbalista, Nadine Varin‐Blank, Fanny Baran‐Marszak, William Vainchenker, Florence Cymbalista, Pierre‐Antoine Deglesne, Nathalie Chevallier, Vincent Lévy, Najet Debili and Frédéric Subra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Rémi Letestu

51 papers receiving 1.1k citations

Peers

Rémi Letestu
María Luz Sánchez Spain
Bernard Lenormand France
Ferdinando Frigeri Italy
Jérôme Rey France
Ana Rasillo Spain
Marie‐Christine Kyrtsonis Greece
Mireia Camós Spain
Andrés Jerez Spain
Guillermo Dighiero Uruguay
Domenico Levato Italy
María Luz Sánchez Spain
Rémi Letestu
Citations per year, relative to Rémi Letestu Rémi Letestu (= 1×) peers María Luz Sánchez

Countries citing papers authored by Rémi Letestu

Since Specialization
Citations

This map shows the geographic impact of Rémi Letestu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rémi Letestu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rémi Letestu more than expected).

Fields of papers citing papers by Rémi Letestu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rémi Letestu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rémi Letestu. The network helps show where Rémi Letestu may publish in the future.

Co-authorship network of co-authors of Rémi Letestu

This figure shows the co-authorship network connecting the top 25 collaborators of Rémi Letestu. A scholar is included among the top collaborators of Rémi Letestu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rémi Letestu. Rémi Letestu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mékinian, A., Anne Quinquenel, Elisabetta Dondi, et al.. (2023). Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression. Cancer Gene Therapy. 30(7). 1018–1028. 8 indexed citations
2.
Quinquenel, Anne, Luc‐Matthieu Fornecker, Rémi Letestu, et al.. (2019). Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 134(7). 641–644. 88 indexed citations
3.
Lazarian, Grégory, Rémi Letestu, Valérie Vidal, et al.. (2019). A primitive plasma cell leukemia with immunoglobulin (Ig) E. Annales de biologie clinique. 77(5). 557–561. 1 indexed citations
4.
Kelaïdi, Charikleia, Thorsten Braun, Alice Marceau‐Renaut, et al.. (2018). Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research. 71. 67–74. 3 indexed citations
5.
Arbabian, Atousa, Jean‐Philippe Brouland, Fanny Baran‐Marszak, et al.. (2017). Induction of endoplasmic reticulum calcium pump expression during early leukemic B cell differentiation. Journal of Experimental & Clinical Cancer Research. 36(1). 87–87. 9 indexed citations
6.
Debliquis, Agathe, Orianne Wagner‐Ballon, Magali Le Garff‐Tavernier, et al.. (2015). Evaluation of Paroxysmal Nocturnal Hemoglobinuria Screening by Flow Cytometry Through Multicentric Interlaboratory Comparison in Four Countries. American Journal of Clinical Pathology. 144(6). 858–868. 4 indexed citations
7.
Neste, Eric Van Den, Rémi Letestu, Thérèse Aurran‐Schleinitz, et al.. (2011). Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia & lymphoma. 53(3). 362–370. 4 indexed citations
8.
Roux‐Villet, C. Le, C. Prost‐Squarcioni, M. Alexandre, et al.. (2011). Rituximab for Patients With Refractory Mucous Membrane Pemphigoid. Archives of Dermatology. 147(7). 843–843. 80 indexed citations
9.
10.
Éclache, Virginie, Bernard Savin, Rémi Letestu, et al.. (2010). Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT‐X) determined by the Sysmex XE‐2100TM. International Journal of Laboratory Hematology. 32(6p1). e237–43. 29 indexed citations
11.
Letestu, Rémi, Vincent Lévy, Virginie Éclache, et al.. (2010). Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 116(22). 4588–4590. 29 indexed citations
12.
Deglesne, Pierre‐Antoine, Rémi Letestu, Nathalie Chevallier, et al.. (2009). Down-regulation of CXCR4 and CD62L in Chronic Lymphocytic Leukemia Cells Is Triggered by B-Cell Receptor Ligation and Associated with Progressive Disease. Cancer Research. 69(16). 6387–6395. 70 indexed citations
13.
Roy, Christine Le, Nadine Varin‐Blank, Florence Ajchenbaum‐Cymbalista, & Rémi Letestu. (2009). Flow cytometry APC‐tandem dyes are degraded through a cell‐dependent mechanism. Cytometry Part A. 75A(10). 882–890. 28 indexed citations
14.
Lefrère, François, Sarah Zohar, Jean‐Antoine Ribeil, et al.. (2007). Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. Transfusion. 47(10). 1851–1857. 29 indexed citations
15.
Cayuela, Jean‐Michel, Chrystèle Bilhou‐Nabera, Claude Gardin, et al.. (2007). Synchronous FIP1L1–PDGFRA‐positive chronic eosinophilic leukemia and T‐cell lymphoblastic lymphoma: a bilineal clonal malignancy. European Journal Of Haematology. 80(1). 81–86. 13 indexed citations
16.
Letestu, Rémi, Christophe Marzac, Ramdane Belhocine, et al.. (2006). Use of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring. Leukemia & lymphoma. 48(1). 89–96. 27 indexed citations
17.
Ugo, Valérie, Nathalie Leporrier, Véronique Salaün, et al.. (2006). Deciphering leukemic B-cell chronic lymphoproliferative disorders. Leukemia & lymphoma. 47(10). 2088–2095. 16 indexed citations
18.
Diop, Saliou, et al.. (2005). [Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia].. PubMed. 50(2). 65–8. 8 indexed citations
19.
Letestu, Rémi, Valérie Ugo, Françoise Valensi, et al.. (2004). Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia. 18(5). 953–961. 15 indexed citations
20.
Massé, Jean‐Marc, et al.. (1999). Intracellular trafficking of the αIIbβ3 receptor antagonist, abciximab, in normal and Glanzmann's disease megakaryocytes. British Journal of Haematology. 107(4). 720–730. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María Luz Sánchez Breakdown of academic impact, for papers by Bernard Lenormand Breakdown of academic impact, for papers by Ferdinando Frigeri Breakdown of academic impact, for papers by Jérôme Rey Breakdown of academic impact, for papers by Ana Rasillo Breakdown of academic impact, for papers by Marie‐Christine Kyrtsonis Breakdown of academic impact, for papers by Mireia Camós Breakdown of academic impact, for papers by Andrés Jerez Breakdown of academic impact, for papers by Guillermo Dighiero Breakdown of academic impact, for papers by Domenico Levato
Rankless by CCL
2026